Personalis, Inc. Form 10-Q Summary
Business context and reporting period
Unaudited quarterly filing for the three and six months ended June 30, 2020. Personalis provides cancer genomics sequencing and data-analysis services for cancer-therapy development and population-sequencing programs. The company operates as one reportable segment, with the U.S. Department of Veterans Affairs Million Veteran Program (VA MVP) representing the majority of revenue.
Key financial metrics
| Metric | Three months ended June 30, 2020 | Six months ended June 30, 2020 |
|---|---|---|
| Revenue | $19.5 million | $38.7 million |
| Gross profit | $4.7 million | $8.7 million |
| Gross margin | 24.0% | 22.5% |
| Loss from operations | $(9.5) million | $(19.1) million |
| Operating margin | (48.7)% | (49.5)% |
| Net loss | $(9.3) million | $(18.4) million |
| Net loss per share | $(0.29) | $(0.58) |
| Net cash used in operating activities | Not separately provided for the quarter | $(24.0) million |
- Revenue increased 23% year over year in the second quarter and 29% in the first half.
- VA MVP revenue was $14.8 million in the quarter and $29.5 million year to date, representing 76% of total revenue in both periods.
- Cash and cash equivalents were $25.0 million, and short-term investments were $80.2 million, for total cash and investments of $105.2 million at June 30, 2020.
- Working capital was $77.1 million. Contract liabilities were $29.0 million, including customer deposits and deferred revenue.
- The company had no outstanding debt at June 30, 2020. The Growth Capital Loan was repaid in full in August 2019.
- Total assets were $145.5 million and stockholders’ equity was $93.1 million at June 30, 2020.
- Capital expenditures were $0.9 million in the first half, while investing cash outflow was $7.7 million primarily because of net purchases of available-for-sale debt securities.
Material changes versus the prior comparable period
- Revenue grew from $15.8 million to $19.5 million in the second quarter and from $29.9 million to $38.7 million in the first half.
- VA MVP revenue increased 73% in the quarter and 75% in the first half, driven by higher sample volumes.
- Revenue from all other customers declined 35% in the quarter and 30% in the first half, primarily because large pharmaceutical project orders recognized in the prior periods did not recur during the transition from the ACE platform to ImmunoID NeXT.
- Costs of revenue increased 49% in the quarter and 50% in the first half, outpacing revenue growth and reducing gross margin. Higher production materials, laboratory personnel, capacity expansion, depreciation, and facility costs were key drivers.
- Research and development expense increased 44% in the quarter and 32% in the first half, reflecting investment in new products and laboratory automation.
- Selling, general and administrative expense increased 41% in the quarter and 55% in the first half due primarily to commercial headcount, professional services, and public-company costs.
- Operating loss widened from $4.1 million to $9.5 million for the quarter and from $9.5 million to $19.1 million for the first half.
- Net loss increased from $5.9 million to $9.3 million for the quarter and from $11.6 million to $18.4 million for the first half. The prior-year periods included interest expense and fair-value losses on preferred-stock warrant liabilities that were largely absent in 2020.
- Weighted-average shares increased substantially because the June 2019 initial public offering and preferred-stock conversion occurred after much of the prior-year comparison period; therefore, the lower per-share loss is not an indication of improved profitability.
Guidance, outlook, commentary, risks, and unusual items
- Management stated that cash and short-term investments, together with expected operating cash flows, should fund near-term capital and operating needs for at least the next 12 months. The filing provides no formal revenue or earnings guidance.
- Management expects continued losses, higher research and development and selling expenses, and additional investment in laboratory capacity, infrastructure, automation, and commercial operations.
- Management expected 2020 property-and-equipment purchases to increase later in the year so that full-year spending would approximate 2019 levels.
- COVID-19 restrictions limited office and laboratory access, reduced productivity, slowed research and development, delayed customer sample shipments, restricted in-person sales activity, and created potential supplier and laboratory-continuity risks. Temporary increased pay for certain laboratory personnel added approximately $0.2 million to second-quarter costs.
- Contracted but unrecognized revenue was $39.3 million at June 30, 2020, which the company expected to recognize within the following nine months. Contract liabilities included approximately $25.2 million of deposits from one customer, creating potential refund and liquidity exposure if services are canceled or reduced.
- Customer concentration is substantial: VA MVP accounted for 76% of revenue, and the top five customers accounted for 94% of quarterly revenue and 91% of first-half revenue.
- The company announced a China partnership in June 2020 and planned a Shanghai structure involving a wholly owned entity and variable-interest entity. The filing highlights regulatory, data-privacy, foreign-investment, currency, intellectual-property, and geopolitical risks related to expansion into China.
- The company relies on Illumina as a sole supplier of sequencers and related reagents and maintenance services. Its master subcontractor agreement with Illumina was scheduled to expire in August 2021.
- The company launched a broad liquid-biopsy assay in August 2020, after the reporting period. The filing does not provide financial results or formal guidance for the product.
- No material legal proceedings, defaults, or off-balance-sheet arrangements were reported. Management concluded that disclosure controls and procedures were effective as of June 30, 2020.
Most important facts for investors to verify
- Whether VA MVP funding, sample volumes, contract renewals, and pricing remain sufficient to support revenue growth and whether customer concentration declines.
- The pace of operating cash burn relative to the $105.2 million cash-and-investment balance and the sustainability of management’s stated 12-month liquidity outlook.
- Whether gross margins improve as laboratory volume, automation, and capacity utilization increase, given that costs grew faster than revenue in the period.
- The amount and terms of customer deposits subject to refund, particularly the approximately $25.2 million deposit from one customer.
- The commercial adoption, regulatory status, and economics of the NeXT Platform, liquid-biopsy assay, diagnostic initiatives, and China expansion.
- Potential effects of COVID-19 disruptions, sole-source supplier dependence, regulatory changes affecting laboratory-developed tests, data-privacy requirements, and intellectual-property claims.
- Future dilution from outstanding options, restricted stock units, employee-plan issuances, and warrants; approximately 6.5 million potentially dilutive securities were excluded from diluted loss-per-share calculations for the quarter.